Calliditas Year-end report, January – December 2023

by

in

STOCKHOLM, Feb. 21, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)

2023: Full approval for TARPEYO in the US; a year of successes

OCTOBER – DECEMBER 2023
(COMPARED TO OCTOBER – DECEMBER 2022)                          

Net sales amounted to SEK 451.6 million, of which TARPEYO® net sales amounted to SEK 347.3 million, for the three months ended December 31, 2023. For the three months ended December 31, 2022, net sales amounted to SEK 429.0 million, of which TARPEYO net sales amounted to SEK 167.3 million.
Operating income amounted to SEK 41.8 million and SEK 32.5 million for the three months ended December 31, 2023, and 2022, respectively.
Loss per share before and after dilution amounted to SEK 0.34 and SEK 0.07 for the three months ended December 31, 2023, and 2022, respectively.
Cash amounted to SEK 973.7 million and SEK 1,249.1 million as of December 31, 2023, and 2022, respectively.

JANUARY – DECEMBER 2023
(COMPARED TO JANUARY –DECEMBER 2022)             

Net sales amounted to SEK 1,206.9 million, of which TARPEYO net sales amounted to SEK 1,075.8 million, for the year ended December 31, 2023. For the year ended December 31, 2022, net sales amounted …

Full story available on Benzinga.com


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *